Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06219941 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06219941 · ClinicalTrials.gov record · last posted 2026-07-29

AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

StatusRecruiting
PhasePhase 2
Started2023-12-13
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The purpose of this study is to assess the safety, tolerability, efficacy, pharmacokinetics (PK), and immunogenicity of AZD0901 as monotherapy and in combination with anti-cancer agents in participants with locally advanced unresectable or metastatic solid tumours expressing CLDN18.2.

Protocol amendment history 2 changes detected by DataLookout

2026-07-30
Primary completion pushed: 2026-08-11 → 2026-11-17
2026-07-30
Completion moved earlier: 2027-09-30 → 2027-06-28
Trial Details
NCT Number NCT06219941
Lead Sponsor AstraZeneca
Conditions Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma
Enrollment 226 participants
Start Date 2023-12-13
Primary Completion 2026-11-17 (estimated)
Study Completion 2027-06-28 (estimated)
Updated on ClinicalTrials.gov 2026-07-29